ArticleImmunity2018
Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c
Open access · bronzeAbstract read
In one paragraph
Article in Immunity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 117 citations in OpenAlex.
- IFNβ-pSTAT1-IRF1 axis controls colorectal tumor development through induction of immunogenic Ly6CNeoplasia (New York, N.Y.) · 2026Article
- Targeting MDSCs in cancer: emerging immunotherapeutic and metabolic strategies.Frontiers in immunology · 2026Review
- Anti-cancer efficacy of novel lonidamine derivatives: Design, synthesis, in vitro, in vivo, and computational studies targeting hexokinase-2.European journal of medicinal chemistry · 2025Article
- Multiple roles of p53 in cancer development: Regulation of tumor microenvironment, mJournal of advanced research · 2025Review
- Harnessing p53 for targeted cancer therapy: new advances and future directions.Transcription · 2025Review
- Heterogeneity of monocytes in cancer.American journal of cancer research · 2025Review
- Guidelines for preparation and flow cytometry analysis of human nonlymphoid tissue DC.European journal of immunology · 2025Article
- MDM2 inhibitors in cancer immunotherapy: Current status and perspective.Genes & diseases · 2024Review
- Engineering dendritic cell biomimetic membrane as a delivery system for tumor targeted therapy.Journal of nanobiotechnology · 2024Review
- p53 at the crossroads of tumor immunity.Nature cancer · 2024Review
- Understanding the complexity of p53 in a new era of tumor suppression.Cancer cell · 2024Review
- Development of Cell Technologies Based on Dendritic Cells for Immunotherapy of Oncological Diseases.Biomedicines · 2024Review
- MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade.Cell death & disease · 2024Article
- Targeted deletion of CD244 on monocytes promotes differentiation into anti-tumorigenic macrophages and potentiates PD-L1 blockade in melanoma.Molecular cancer · 2024Article
- Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models.Theranostics · 2024Article
- The cholera toxin B subunit induces trained immunity in dendritic cells and promotes CD8 T cell antitumor immunity.Frontiers in immunology · 2024Article
- Reduced Ceramides Are Associated with Acute Rejection in Liver Transplant Patients and Skin Graft and Hepatocyte Transplant Mice, Reducing Tolerogenic Dendritic Cells.Molecules and cells · 2023Article
- Pharmacological potentiation of monocyte-derived dendritic cell cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2023Review
- Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions.Pharmacology & therapeutics · 2023Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
19 authors at 5 institutions in 2 countries.
Madhav D SharmaGeorgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA; Department of Pediatrics, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Paulo C RodriguezGeorgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Brent H KoehnDepartment of Pediatrics and Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN 55455, USA.
Babak BabanDental College of Georgia, Augusta University, Augusta, GA 30912, USA.
Yan CuiGeorgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA; Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Gang GuoGeorgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA; Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Michiko ShimodaGeorgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Rafal PacholczykGeorgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Huidong ShiGeorgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA; Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Eun-Joon LeeGeorgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA; Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Hongyan XuGeorgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA; Department of Population Health Science, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Theodore S JohnsonGeorgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA; Department of Pediatrics, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Yukai HeGeorgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Taha MergoubDepartment of Medicine, Immunology Program and Ludwig Center, Memorial Sloan Kettering Cancer Center; Weill Cornell Medical School and Graduate School of Biomedical Sciences; and Ludwig Institute for Cancer Research, New York, NY 10065, USA.
Christopher VenableGeorgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Vincenzo BronteUniversity Hospital and Department of Medicine, University of Verona, Verona 37134, Italy.
Jedd D WolchokDepartment of Medicine, Immunology Program and Ludwig Center, Memorial Sloan Kettering Cancer Center; Weill Cornell Medical School and Graduate School of Biomedical Sciences; and Ludwig Institute for Cancer Research, New York, NY 10065, USA.
Bruce R BlazarDepartment of Pediatrics and Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN 55455, USA.
David H MunnGeorgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA; Department of Pediatrics, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA. Electronic address: dmunn@augusta.edu.
Augusta University · USUniversity of Minnesota · USCornell University · USLudwig Cancer Research · USUniversity of Verona · IT
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MReprogramming the TME for immunogenic antigen-presentationR01CA103320 · NCI · MEDICAL COLLEGE OF GEORGIA (MCG) · PI MUNN, DAVID H. · 2003 to 2024
$6.0MT-CELL TARGETING FOR GVHDR01HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1995 to 2022
$5.4MGVL TO REDUCE AML RELAPSE AFTER MURINE ALLOGENEIC BMTR01CA072669 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1997 to 2017
$4.9MT CELL TARGETING FOR GVHDR37HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R. · 1998 to 2007
$3.2MStress Pathways in Tumors Drive Global MDSC Activity and Survival through ChopR01CA184185 · NCI · LSU HEALTH SCIENCES CENTER · PI RODRIGUEZ, PAULO CESAR · 2015 to 2019
$1.8MPTEN, Tregs and MDSCs in the tumor microenvironmentR01CA211229 · NCI · AUGUSTA UNIVERSITY · PI MUNN, DAVID H. · 2017 to 2021
$1.7MP53 inactivation on MDSC development and tumor progressionR01CA169133 · NCI · LSU HEALTH SCIENCES CENTER · PI CUI, YAN · 2013 to 2017
$1.5MNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA072669NCI NIH HHS R01 CA103320NCI NIH HHS R01 CA169133NCI NIH HHS R01 CA184185NCI NIH HHS R01 CA211229NHLBI NIH HHS R01 HL056067NHLBI NIH HHS R37 HL056067
Abstract
CD103
Indexed as
AnimalsAntigen-Presenting CellsAntigens, CDAntigens, LyCell DifferentiationCell LineFlow CytometryHumansImmunotherapyIntegrin alpha ChainsMiceMonocytesMyeloid CellsNeoplasmsTumor Suppressor Protein p53alpha E integrinsAntigens, CDAntigens, LyIntegrin alpha ChainsLy-6C antigen, mouseTumor Suppressor Protein p53Batf3cancerCD103cDCdendritic cellsimmunotherapyMDSCmyeloid-derived suppressor cellsp53PTENtumor immunology
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.